Goldman Sachs Upgrades Ryan Specialty Holdings to Buy, Announces $47 Price Target
Goldman Sachs analyst Robert Cox upgrades Ryan Specialty Holdings (NYSE:RYAN) from Neutral to Buy and announces $47 price target.
RBC Capital Maintains Outperform on Targa Resources, Raises Price Target to $100
RBC Capital analyst TJ Schultz maintains Targa Resources (NYSE:TRGP) with a Outperform and raises the price target from $90 to $100.
RBC Capital Maintains Sector Perform on New Gold, Lowers Price Target to $1
RBC Capital analyst Michael Siperco maintains New Gold (AMEX:NGD) with a Sector Perform and lowers the price target from $1.5 to $1.
Goldman Sachs Initiates Coverage On Marsh & McLennan with Buy Rating, Announces Price Target of $182
Goldman Sachs analyst Robert Cox initiates coverage on Marsh & McLennan (NYSE:MMC) with a Buy rating and announces Price Target of $182.
Credit Suisse Maintains Neutral on Gap, Lowers Price Target to $8
Credit Suisse analyst Michael Binetti maintains Gap (NYSE:GPS) with a Neutral and lowers the price target from $10 to $8.
BMO Capital Upgrades Fate Therapeutics to Outperform, Lowers Price Target to $47
BMO Capital analyst Etzer Darout upgrades Fate Therapeutics (NASDAQ:FATE) from Market Perform to Outperform and lowers the price target from $50 to $47.
Mizuho Maintains Buy on Public Service Enterprise, Lowers Price Target to $68
Mizuho analyst Paul Fremont maintains Public Service Enterprise (NYSE:PEG) with a Buy and lowers the price target from $73 to $68.
BMO Capital Downgrades Macrogenics to Market Perform, Lowers Price Target to $4
BMO Capital analyst Etzer Darout downgrades Macrogenics (NASDAQ:MGNX) from Outperform to Market Perform and lowers the price target from $31 to $4.
Goldman Sachs Initiates Coverage On Allscripts Healthcare with Neutral Rating, Announces Price Target of $21
Goldman Sachs analyst Cindy Motz initiates coverage on Allscripts Healthcare (NASDAQ:MDRX) with a Neutral rating and announces Price Target of $21.
Goldman Sachs Initiates Coverage On Willis Towers Watson with Neutral Rating, Announces Price Target of $227
Goldman Sachs analyst Robert Cox initiates coverage on Willis Towers Watson (NASDAQ:WTW) with a Neutral rating and announces Price Target of $227.